The initial success of Sildenafil undeniably revolutionized the drug landscape, but placing funds in companies strongly reliant on off-patent versions presents a challenging picture. While early earnings were impressive, the cessation of patents and the appearance of less expensive alternatives have eroded sales. Consequently, a thorough evaluation